Updates are available Correction dated 2024-06-16

Article History

Received: 2 October 2023

Accepted: 11 March 2024

First Online: 27 March 2024

Change Date: 16 June 2024

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1186/s13613-024-01322-1

Declarations

:

: The local ethics committee (Kantonale Ethikkommission Zürich; study ID: 2020 − 00719) and the national authorization and supervisory authority for drugs and medical products (Swissmedic; study ID: 2020DR3050) approved the trial (date: April 9, 2020; study title: “sevoflurane sedation in COVID-19 ARDS patients to reduce lung injury: a randomized controlled trial.). The local ethics committee (Kantonale Ethikkommission Zürich; study ID: 2020 − 00719) and the national authorization and supervisory authority for drugs and medical products (Swissmedic; study ID: 2020DR3050) approved the trial (date: April 9, 2020; study title: “sevoflurane sedation in COVID-19 ARDS patients to reduce lung injury: a randomized controlled trial”). Because patients were under sedation at the time of enrollment into the trial, the study team obtained consent from an independent physician not involved in this research project which was consulted to protect the patient’s interests. The patient’s legal representative was approached as soon as possible, at least within 7 days after enrollment, and informed about the nature of the trial. Post-hoc written and informed consent was obtained from the patient or the legal representative (in patients not regaining decisional capacity within 7 days). Lack of written consent resulted in study exclusion. The trial was conducted in accordance with ethical standards, national legislation, and the Helsinki Declaration.

: Not applicable.

: Martin Schläpfer and Beatrice Beck-Schimmer have received unrestricted research funds from Sedana Medical, Danderyd, Sweden, and from Roche Diagnostics International, Rotkreuz, Switzerland. Beatrice Beck-Schimmer and Martin Schläpfer have submitted a patent to mitigate the negative effects of surgery and/or anesthesia for patients using medical gases, particularly oxygen (O2) and carbon dioxide (CO2). Beatrice Beck Schimmer submitted US and EP patent applications for an injectable formulation for the treatment and protection of patients having an inflammatory reaction or an ischemia/reperfusion event. Erik Schadde, Urs Pietsch, Miodrag Filipovic, Seraina Dübendorfer-Dalbert, Patricia Fodor, Tobias Hübner, Reto Schuepbach, Peter Steiger, Sascha David, Bernard D. Krüger and Thomas A. Neff have no conflicts of interest to declare.